» Articles » PMID: 38967023

Structural Insight into the Csx1-Crn2 Fusion Self-limiting Ribonuclease of Type III CRISPR System

Overview
Specialty Biochemistry
Date 2024 Jul 5
PMID 38967023
Authors
Affiliations
Soon will be listed here.
Abstract

In the type III CRISPR system, cyclic oligoadenylate (cOA) molecules act as second messengers, activating various promiscuous ancillary nucleases that indiscriminately degrade host and viral DNA/RNA. Conversely, ring nucleases, by specifically cleaving cOA molecules, function as off-switches to protect host cells from dormancy or death, and allow viruses to counteract immune responses. The fusion protein Csx1-Crn2, combining host ribonuclease with viral ring nuclease, represents a unique self-limiting ribonuclease family. Here, we describe the structures of Csx1-Crn2 from the organism of Marinitoga sp., in both its full-length and truncated forms, as well as in complex with cA4. We show that Csx1-Crn2 operates as a homo-tetramer, a configuration crucial for preserving the structural integrity of the HEPN domain and ensuring effective ssRNA cleavage. The binding of cA4 to the CARF domain triggers significant conformational changes across the CARF, HTH, and into the HEPN domains, leading the two R-X4-6-H motifs to form a composite catalytic site. Intriguingly, an acetate ion was found to bind at this composite site by mimicking the scissile phosphate. Further molecular docking analysis reveals that the HEPN domain can accommodate a single ssRNA molecule involving both R-X4-6-H motifs, underscoring the importance of HEPN domain dimerization for its activation.

References
1.
Brown S, Gauvin C, Charbonneau A, Burman N, Lawrence C . Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA. J Biol Chem. 2020; 295(44):14963-14972. PMC: 7606696. DOI: 10.1074/jbc.RA120.014099. View

2.
Molina R, Garcia-Martin R, Lopez-Mendez B, Jensen A, Ciges-Tomas J, Marchena-Hurtado J . Molecular basis of cyclic tetra-oligoadenylate processing by small standalone CRISPR-Cas ring nucleases. Nucleic Acids Res. 2022; 50(19):11199-11213. PMC: 9638899. DOI: 10.1093/nar/gkac923. View

3.
Rostol J, Marraffini L . Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity. Nat Microbiol. 2019; 4(4):656-662. PMC: 6430669. DOI: 10.1038/s41564-018-0353-x. View

4.
Bunkoczi G, Echols N, McCoy A, Oeffner R, Adams P, Read R . Phaser.MRage: automated molecular replacement. Acta Crystallogr D Biol Crystallogr. 2013; 69(Pt 11):2276-86. PMC: 3817702. DOI: 10.1107/S0907444913022750. View

5.
Kazlauskiene M, Kostiuk G, Venclovas C, Tamulaitis G, Siksnys V . A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Science. 2017; 357(6351):605-609. DOI: 10.1126/science.aao0100. View